Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 801 - 850 of 1868 results
- Human Matrix Metalloproteinase-8 Gene Delivery Increases the Oncolytic Activity of a Replicating Adenovirus.
- Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
- New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.
- Targeting of Insulin-like Growth Factor-I Receptor with a Monoclonal Antibody Inhibits Growth of Hepatic Metastases from Human Colon Carcinoma in Mice.
- Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated?
- Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
- The farnesyltransferase inhibitor R115777 (ZARNESTRA(R)) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.
- Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles.
- Phase II Trial of Sorafenib Plus Interferon Alfa-2b As First- or Second-Line Therapy in Patients With Metastatic Renal Cell Cancer.
- Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group.
- Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
- Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.
- A Phase I Clinical Trial of Single-Dose Intrapleural IFN-{beta} Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses.
- Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses.
- Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma.
- Augmented Antitumor Activity against B-Cell Lymphoma by a Combination of Monoclonal Antibodies Targeting TRAIL-R1 and CD20.
- A Human scFv Antibody against TRAIL Receptor 2 Induces Autophagic Cell Death in Both TRAIL-Sensitive and TRAIL-Resistant Cancer Cells.
- Targeting Human {gamma}{delta} T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer.
- A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
- Combined natural killer T-cell based immunotherapy eradicates established tumors in mice.
- CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models.
- Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study.
- Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy.
- Virulizin((R)), a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo.
- Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy.
- Transfection with CD40L induces tumoursuppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma.
- A Pegylated Derivative of {alpha}-Galactosylceramide Exhibits Improved Biological Properties.
- Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting.
- Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
- Ty21a expressing Human papillomavirus type 16 L1 as a potential live Salmonella vaccine against cervical cancer and typhoid fever.
- Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
- Functional and phenotypic characteristics of CD4(+)CD25(high)Foxp3(+) Treg clones obtained from peripheral blood of patients with cancer.
- Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice.
- An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-{alpha}2b in patients with multiple myeloma maintained on a steady dose of interferon-{alpha}2b.
- Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
- Role of CXCL12 in metastasis of human ovarian cancer.
- Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo.
- Alteration of dihydropyrimidine dehydrogenase expression by IFN-{alpha} affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells.
- Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses.
- Enhancement of Anti-Melanoma Activity of a Plasmid Expressing HIV-1 Vpr Delivered Through In Vivo Electroporation.
- Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
- Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
- A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients.
- Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
- A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
- A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
- Toward the Development of Prophylactic and Therapeutic Human Papillomavirus Type-16 Lipopeptide Vaccines.
- Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer.
- Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
- 15-Deoxy-Delta(12,14)-prostaglandin J(2) down-regulates CXCR4 on carcinoma cells through PPARgamma- and NFkappaB-mediated pathways.